Gro Bioscences, a Boston MA-based biotechnology company that advances protein therapeutics, has raised $ 25 million in Series A funding.
The cycle was led by Leaps by Bayer and Redmile Group with the participation of Digitalis Ventures and Innovation Endeavors.
The company intends to use the funds to scale up its bioprocess manufacturing, preclinical validation studies, and IND studies for its pipeline of Nonstandard Amino Acid Protein Therapies (NSAAs) to treat auto diseases. -immune and metabolic.
Led by Daniel J. Mandell, PhD, CEO, GRO Biosciences is a biotechnology company that leverages science to expand the amino acid alphabet and advance protein therapy in various fields including autoimmune and metabolic diseases . The company applies its platform to advance partnership and collaborative programs, as well as its own pipeline of therapeutic proteins carrying unique NSAA (non-standard amino acid) chemistries.
The proprietary platform, developed in the labs of Dr George Church, is made up of the first production organisms with modified genomes that enable the production of proteins with NSAAs – building blocks of proteins that grow beyond 20 typical amino acids. The company’s scalable and stable production platform delivers therapeutic proteins with chemistries and properties previously inaccessible to protein engineering.